| Similar Articles |
|---|
 |
The Motley Fool
July 28, 2010
Brian Orelli |
Fighting Hard to Keep a Blockbuster Sanofi is suing the FDA to take back approval of a competing generic drug. Did you expect something different?   |
The Motley Fool
February 14, 2008
Brian Lawler |
Sanofi Stagnates French drugmaker Sanofi-Aventis posts fourth-quarter earnings in which its top drugs get some protection, but free cash flow drops. |
The Motley Fool
October 31, 2007
Brian Lawler |
Sanofi: Stable, for Now The drugmaker's healthy Q3 results shine amid slumping competitors. Investors, take note. |
The Motley Fool
October 30, 2009
Brian Orelli |
Shrugging Off the Side Effects Sanofi-aventis is looking good, but still faces the patent protection loss of Lovenox. |
The Motley Fool
May 15, 2008
Brian Orelli |
Wanted: FDA Approval -- Pronto Teva and Amphastar have the courts on their side, but the FDA still stands in the way of a generic-drug launch. |
The Motley Fool
February 11, 2010
Brian Orelli |
A Turnaround Year, But Not in a Good Way 2009 was a solid year for sanofi-aventis thanks to a boost from sales of swine flu vaccine and some help from the exchange rate. But 2010? Not so solid. |
The Motley Fool
April 10, 2007
Brian Lawler |
Barr Issues a Challenge Barr challenges the patents on one of Sanofi's top drugs. |
The Motley Fool
September 11, 2007
Brian Lawler |
Where Momenta Stands Momenta Pharmaceuticals updates investors as to the status of drugs in its pipeline. Until the FDA makes up its mind on its lead drug, an anticoagulant, it's anyone's guess as to what the value of the pipeline is. Investors should take note. |
The Motley Fool
November 26, 2010
Brian Orelli |
Black Friday Biotech Bargains Drugmakers on sale. |
The Motley Fool
July 23, 2010
Luke Timmerman |
Momenta Gets FDA Green Light for Generic Anti-Clotting Drug The FDA says "yes" to Momenta Pharmaceuticals. |
The Motley Fool
November 2, 2010
Travis Hoium |
Momenta Pharmaceuticals Shares Plunged: What You Need to Know Momenta Pharmaceuticals shares fell 10% in trading early Tuesday after Teva Pharmaceutical Industries said it expects FDA approval this year on a drug to compete with Momenta's enoxaparin. |
The Motley Fool
January 5, 2010
Brian Orelli |
Lilly's Effient: Cheap Enough, for Now In order to justify the use of Effient, Eli Lilly is touting a study published in today's Circulation demonstrating the cost effectiveness of Effient over Plavix. |
The Motley Fool
June 18, 2010
Brian Orelli |
Double the Approvals! Double the Fun! These twins will take it. sanofi-aventis and Novartis both received FDA approvals for their cancer drugs yesterday. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
November 7, 2007
Brian Orelli |
Momenta Stopped Momenta and Novartis receive a not-approvable letter for their new drug application on their generic version of Lovenox, due to worries that it might cause an immune reaction. Investors, take note. |
The Motley Fool
August 30, 2010
Brian Orelli |
Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help. |
The Motley Fool
December 11, 2006
Brian Lawler |
Weighing In on Sanofi's Acomplia With the future of Sanofi's two top drugs in the hands of the courts, plus any Acomplia approval subject to the whims of the FDA, investors should wait on the sidelines until these judicial and regulatory decisions have been made. |
The Motley Fool
August 25, 2010
Brian Orelli |
Shares Soar! That'll Help Investors Sleep Better Tonight. Somaxon finds a marketing partner for its insomnia drug. |
The Motley Fool
July 21, 2011
Brian Orelli |
Keep an Eye on Biotech Partners' Earnings Novartis' earnings are important for small biotechs Momenta and Vanda. |
The Motley Fool
May 9, 2007
Brian Lawler |
Where Is Momenta's Momentum? Momenta awaits an FDA regulatory decision and announces quarterly financial results. Investors, take note. |
The Motley Fool
October 26, 2011
Brian Orelli |
Momenta Stopped. Again. Oh, no - an authorized generic gets launched. |
The Motley Fool
November 1, 2010
Brian Orelli |
Stock Doubles! No Crying Here AVANIR Pharmaceuticals' investors didn't have any uncontrolled crying on Friday when the Food and Drug Administration approved Nuedexta, the company's treatment for pseudobulbar affect. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
March 23, 2010
Brian Orelli |
No Patent! No Generics? Take Advantage of the Situation Enjoy it while it lasts, pharma. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
The Motley Fool
April 16, 2010
Brian Orelli |
It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet. |
The Motley Fool
December 14, 2007
Brian Lawler |
FDA Knocks Neurocrine a Knuckle Sandwich The FDA clobbers drugmaker Neurocrine with another delay. |
The Motley Fool
February 25, 2008
Brian Lawler |
The Most Interesting FDA Review for 2008 Eli Lilly preps for an upcoming FDA review of its top pipeline drug, the blood thinner prasugrel. |
The Motley Fool
February 15, 2007
Brian Lawler |
A Momenta's Pause The pharmaceutical elaborates on plans for its generic version of blockbuster Lovenox. With so much going on, the rest of 2007 is sure to be a wild ride for Momenta investors. |
The Motley Fool
May 7, 2007
Brian Lawler |
Sanofi Rolls the Lawsuit Dice Investors, don't be fooled by rosy results; litigation risk still looms for the French drugmaker. |
The Motley Fool
August 23, 2010
Brian Orelli |
No Way to Jazz Up This Result Jazz Pharmaceuticals investors went from ecstatic to devastated in less than a week. |
The Motley Fool
July 28, 2010
Jordan DiPietro |
3 Biotechs on Your Radar Screen It's not easy keeping track of all the drugs coming in and out of the development pipeline, but if you can stay up to date, you often have an advantage |
The Motley Fool
June 27, 2008
Brian Lawler |
Vanda's Drug Draws a Yawn Shares of Vanda Pharmaceuticals have fallen more than 20% recently, even though the company said that its phase 3 clinical trial met its primary goal. |
The Motley Fool
June 2, 2008
Brian Orelli |
The Anticoagulation Competition Bloodbath Bayer and Johnson & Johnson give Sanofi's Lovenox another beating. |
The Motley Fool
December 30, 2010
Brian Orelli |
2011 Drugmaker M&A Targets What Big Pharma M&A deals will 2011 hold? Most likely, more small deals, and perhaps Sanofi will finally offer a reasonable price for Genzyme. Let's take a look at some of the companies that might be walking down the aisle next year. |
The Motley Fool
November 6, 2006
Brian Lawler |
The Impending Verdict on Momenta The drug developer isn't willing to wait for potential legislation on generic drugs. Investors, take note. |
The Motley Fool
January 19, 2007
Karl Thiel |
The Best Drug Stock for 2007: Momenta Investors, swing for the fences with this drug company. |
The Motley Fool
December 8, 2010
Brian Orelli |
Up 100% With Room to Fly Orexigen gets a positive FDA panel nod. |
The Motley Fool
February 20, 2007
Brian Lawler |
Sanofi Sweats the Generic Drugmaker Sanofi-Aventis releases fourth-quarter earnings numbers and guidance for the year ahead. |
The Motley Fool
July 27, 2010
Brian Orelli |
Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts. |
The Motley Fool
March 15, 2010
Brian Orelli |
Warning: Not All Boxed Warnings Are Equal Plavix's is mild in comparison. |
The Motley Fool
September 9, 2010
Brian Orelli |
Will These Drugs Get Past the FDA This Month? See what the FDA has on its decision calendar for the rest of September. |
The Motley Fool
September 30, 2008
Brian Lawler |
No Approval for You ... Yet The FDA makes Eli Lilly wait for word on a lead drug. |
The Motley Fool
July 27, 2010
Brian Orelli |
Brilinta? I Think Not. AstraZeneca's new blood thinner is far from brilliant. |
The Motley Fool
January 28, 2011
Brian Orelli |
Looking Ahead at Bristol-Myers Product approvals now will help with the upcoming patent cliff. |
The Motley Fool
August 13, 2004
Charly Travers |
Smaller Market for Insomnia Drugs A market research report shows insurers might not cover some drugs for this condition. |
The Motley Fool
May 2, 2011
Tim Beyers |
Spectrum Pharmaceuticals Shares Popped: What You Need to Know Shares of Spectrum Pharmaceuticals rose as much as 14% in intraday trading after the Food and Drug Administration approved Fusilev as a colon cancer treatment. |
BusinessWeek
January 26, 2004
Arelene Weintraub |
"Exploring New Paradigms in Sleep" Two top execs from Sanofi, maker of the popular drug Ambien, talk about the challenges of staying on top in the insomnia market. |
The Motley Fool
December 2, 2010
Brian Orelli |
A Short FDA Delay. For What? GlaxoSmithKline and Valeant aren't saying. |
The Motley Fool
October 4, 2010
Brian Orelli |
That's No Way to Make Friends Sanofi goes hostile on Genzyme. |
